TOKYO, August 24, 2026 | DRC Medicine is asking SPAC investors to approve a $350 million equity value for a Japanese healthcare company that produced less than $300,000 of revenue in its latest fiscal year and still depends on outside capital. The September 10 shareholder vote will decide whether DRC reaches Nasdaq under the proposed symbol DRC, but redemptions will decide how much financing value the listing actually delivers.

The final proxy statement and prospectus, dated August 21 and filed Monday, registers up to 40,803,846 shares for the combination with Ribbon Acquisition Corp. The document solicits a merger vote. Ribbon shareholders may redeem their public shares, and the new DRC shares will be issued largely as merger consideration. No newly underwritten $10 stock sale is part of the transaction. The extraordinary general meeting is scheduled for September 10 at 10 a.m. Eastern time.

The funding outcome has a wide range

At announcement in June 2025, the parties presented the transaction as a route to roughly $50 million of cash from Ribbon's trust, assuming no redemptions and before expenses. The deal announcement put DRC's pre-money equity value at $350 million and the combined company's initial pro forma equity value at about $422.2 million. Existing DRC holders were expected to own about 82.9% with no redemptions.

The final prospectus sharpens that picture. DRC estimates approximately $47.4 million of cash immediately after closing in the no-redemption case, after transaction expenses and required payments. The estimate falls to about $21.7 million under an intermediate-redemption case and to minimal cash at maximum redemptions. IPOGrid reads that spread as the central deal variable. The vote can deliver a Nasdaq listing while producing far less growth capital than the headline trust balance suggests.

There is no identified PIPE or third-party cornerstone commitment in the final terms. The $2.2 million private placement highlighted in the transaction history was the sponsor's purchase of 220,000 units alongside Ribbon's January 2025 IPO. It funded the SPAC setup and gives the sponsor capital at risk; it is not fresh concurrent financing for DRC at the merger closing. A.G.P./Alliance Global Partners is Ribbon's financial and lead capital-markets adviser, while Geneva Capital Group advises DRC, according to the transaction release. There is no conventional IPO bookrunner building demand for new DRC shares.

A public valuation far ahead of current scale

DRC describes itself as a healthcare and biotechnology company built around Hydro Silver Titanium, a protein-degrading material used in masks, towels and other hygiene products. Its corporate site also presents programs across allergy, infectious disease, medical devices and drug development. That breadth gives the public-market story multiple possible routes to value, but the present financial base is narrow.

Revenue fell 30.5% to $265,803 in the nine months ended April 30, 2026, from $382,347 a year earlier. For the three-month period, revenue declined 9% to $114,015. For the fiscal year ended July 31, 2025, DRC reported $294,937 of revenue, a $1.68 million net loss and $1.17 million of operating cash use. It finished that fiscal year with $284,303 in cash, approximately $6.18 million of liabilities and a $6.41 million accumulated deficit. Those figures, and the company's going-concern warning, appear in the final prospectus.

Our interpretation is that investors are being asked to value commercialization optionality rather than an established operating business. The $350 million base equity value equals roughly 1,187 times fiscal 2025 revenue. That simple multiple is not a biotech valuation method, but it shows how little support the current income statement provides. Regulatory progress, licensing economics and product adoption will have to carry the thesis.

Control remains concentrated

DRC shareholders receive 35 million new shares in the combination. Chief executive Narumi Okazaki is expected to own about 43.2% of the post-closing company if no Ribbon public shares are redeemed and about 47.3% if all are redeemed. DRC will also designate six of the seven directors. The reviewer’s concern is straightforward: public investors would supply liquidity and a listing while governance remains firmly anchored with the pre-merger company.

Nasdaq acceptance remains a closing condition, and the prospectus says DRC has applied to list the combined company's common stock under DRC. It also cautions that approval and continued compliance are not assured. Ribbon, meanwhile, has required monthly extensions to keep the transaction window open. Its March-quarter report said $500,000 had been deposited into trust across four monthly extensions through April.

The September 10 vote therefore marks a real launch point. The decisive market event will be the redemption tally, followed by the closing cash balance and confirmation of Nasdaq approval. For DRC, those three items will say more about the quality of the public-market debut than the 40.8 million shares printed on the prospectus cover.